CLRB
Cellectar Biosciences, Inc.
There isn't enough reported data to score CLRB yet.
CLRB Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Weak | |
| Unavailable | |
| Unavailable |
CLRB's profitability is currently weak. There isn't enough data to rate its revenue, cash flow and balance sheet.
CLRB PE Valuation
CLRB has no meaningful PE right now: it lost money over the past year.
CLRB Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong decline | |
| -- | |
| Limited | |
| Low |
Analysts expect CLRB's losses to shrink, with revenue declining. However, they disagree widely on these estimates.
CLRB Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2024 | -$57.00 | +$63.86 |
| Q2 2024 | -$81.30 | +$41.66 |
| Q1 2024 | -$97.80 | +$39.86 |
| Q4 2023 | -$89.66 | +$58.99 |
CLRB is still losing money, but far less than before: $5.77 per share over the past year, against $552.00 at its worst in late 2019.
CLRB Quarterly Revenue
CLRB Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q4 2025 | -$4.3M | +$6.6M |
| Q4 2024 | -$11M | -$1.1M |
| Q1 2024 | -$13.4M | -$6.2M |
| Q4 2023 | -$9.9M | -$2.3M |
| Q1 2023 | -$7.2M | -$2.1M |
| Q4 2022 | -$7.5M | -$2.9M |
| Q3 2022 | -$7M | -$587.1K |
| Q4 2021 | -$4.6M | -$754.8K |
CLRB has burned cash in almost every quarter: −$25M over the past year, against −$48M the year before.
CLRB Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +43% | +5.2M shares |
| 1 year | +985% | +15.9M shares |
| 3 years | +4552% | +17.1M shares |
| 5 years | +19799% | +17.4M shares |
CLRB has 17M diluted shares, up 985% from a year ago.
| Quarter | Spent |
|---|---|
| Q1 2023 | — |
| Q1 2022 | — |
CLRB Net Leverage
CLRB's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
CLRB Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 28.4 | Oversold |
| Stochastic | 5.8 | Oversold |
CLRB's weekly RSI is 28 (oversold) and its Stochastic is 6 (oversold).
CLRB PE vs Healthcare Sector
CLRB has no meaningful PE right now: it lost money over the past year.
CLRB Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.38 | 16% below |
| 20 week MA | $2.07 | 44% below |
| 50 week MA | $2.65 | 56% below |
| 100 week MA | $4.78 | 76% below |
| 200 week MA | $37.3 | 97% below |
CLRB is in a downtrend: it's below all five of its weekly moving averages, and 97% below its 200-week average.
CLRB Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $651.0 | $660.0 | +1.4% |
| 2021 | $660.0 | $210.0 | -68% |
| 2022 | $210.0 | $46.5 | -78% |
| 2023 | $46.5 | $83.1 | +79% |
| 2024 | $83.1 | $9.26 | -89% |
| 2025 | $9.26 | $2.56 | -72% |
| 2026 YTD | $2.56 | $1.16 | -55% |
CLRB has finished lower in four of the last six years. It's down 55% so far in 2026.